Date & Time :  27 October 2026 | 16:00–17:15 CEST | Online

 

 

 

Sarcomas are rare, heterogeneous tumours requiring specialised multidisciplinary care. Many radiation oncology departments see low case volumes, leading to variability in practice. This ESTRO webinar covers  up-to-date advances in sarcoma management that are directly relevant to daily radiotherapy practice, such as guidelines, paediatric and dermal sarcomas, hypofractionation, and translational research.

 

Chairs

Agata Rembielak, MD PhD, Co-Chair of ESTRO Skin and Soft Tissue Focus Group, Consultant in Clinical and Radiation Oncology, The Christie NHS Foundation Trust and The University of Manchester (UK) — Chair

Mateusz Spałek, MD PhD, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Poland) — Co-Chair

 

Speakers

• Siyer Roohani, Universitätsklinikum Hamburg Eppendorf (Germany) — "Guidelines and caveats in radiotherapy for sarcomas"

• Beate Timmermann, Co-Chair of ESTRO Skin and Soft Tissue Focus Group, Universitätsklinikum Essen (Germany) — "Paediatric sarcomas"

• Franziska Eckert, Medical University of Vienna (Austria) — "Organoids and translational sarcoma research"

• Bruno Fionda, Policlinico Universitario Agostino Gemelli (Italy) — "Dermal sarcomas"

• Mateusz Spałek, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Poland) — "Hypofractionation in sarcoma"

 

Programme

16:00 – 16:05 | Introduction by Chairs

16:05 – 16:17 | Talk 1: Guidelines and caveats in radiotherapy for sarcomas (Roohani)

16:17 – 16:29 | Talk 2: Paediatric sarcomas (Timmermann)

16:29 – 16:41 | Talk 3: Organoids and translational sarcoma research (Eckert)

16:41 – 16:53 | Talk 4: Dermal sarcomas (Fionda)

16:53 – 17:05 | Talk 5: Hypofractionation in sarcoma (Spałek)

17:05 – 17:15 | Panel discussion and audience Q&A

 

Key Learning Objectives

1. Review current radiotherapy guidelines and pitfalls in sarcoma management.

2. Recognise the specific considerations in treating paediatric sarcomas.

3. Understand the role of organoids and translational research in sarcoma practice.

4. Discuss the management of dermal sarcomas and evolving evidence.

5. Evaluate the role of hypofractionation in sarcoma radiotherapy and identify relevant ESTRO resources for ongoing learning.

 

Resources

Hypofractionation in sarcoma

1. Salerno KE, Alektiar KM, Baldini EH, et al. Radiation therapy for treatment of soft tissue sarcoma in adults: Executive summary of an ASTRO clinical practice guideline. *Pract Radiat Oncol.* 2021;11(5):339-351. doi:10.1016/j.prro.2021.04.005.

2. O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. *Lancet.* 2002;359(9325):2235-2241. doi:10.1016/S0140-6736(02)09292-9.

3. Koseła-Paterczyk H, Szacht M, Morysiński T, et al. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. *Eur J Surg Oncol.* 2014;40(12):1641-1647. doi:10.1016/j.ejso.2014.05.016.

4. Koseła-Paterczyk H, Teterycz P, Spałek MJ, et al. Efficacy and safety of hypofractionated preoperative radiotherapy for primary locally advanced soft tissue sarcomas of limbs or trunk wall. *Cancers (Basel).* 2021;13(12):2981. doi:10.3390/cancers13122981. 

5. Kalbasi A, Kamrava M, Chu FI, et al. A phase II trial of 5-day neoadjuvant radiotherapy for patients with high-risk primary soft tissue sarcoma. *Clin Cancer Res.* 2020;26(8):1829-1836. doi:10.1158/1078-0432.CCR-19-3524.

6. Guadagnolo BA, Bassett RL, Mitra D, et al. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): A single-centre, open-label, single-arm, phase 2 trial. *Lancet Oncol.* 2022;23(12):1547-1557. doi:10.1016/S1470-2045(22)00638-6. 

7. Bedi M, Singh R, Charlson JA, et al. Is 5 the new 25? Long-term oncologic outcomes from a phase II, prospective, 5-fraction preoperative radiation therapy trial in patients with localized soft tissue sarcoma. *Adv Radiat Oncol.* 2022;7(2):100850. doi:10.1016/j.adro.2021.100850.

8. Leite ETT, Munhoz RR, Camargo VP, et al. Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities. *Radiother Oncol.* 2021;161:222-229. doi:10.1016/j.radonc.2021.06.027.

9. Spałek MJ, Koseła-Paterczyk H, Borkowska A, et al. Combined preoperative hypofractionated radiotherapy with doxorubicin-ifosfamide chemotherapy in marginally resectable soft tissue sarcomas: Results of a phase 2 clinical trial. *Int J Radiat Oncol Biol Phys.* 2021;110(4):1053-1063. doi:10.1016/j.ijrobp.2021.02.019. 

10. Spałek MJ, Borkowska AM, Telejko M, et al. The feasibility study of hypofractionated radiotherapy with regional hyperthermia in soft tissue sarcomas. *Cancers (Basel).* 2021;13(6):1332. doi:10.3390/cancers13061332.

11. Gobo Silva ML, Lopes de Mello CA, Aguiar Junior S, et al. Neoadjuvant hypofractionated radiotherapy and chemotherapy for extremity soft tissue sarcomas: Safety, feasibility, and early oncologic outcomes of a phase 2 trial. *Radiother Oncol.* 2021;159:161-167. doi:10.1016/j.radonc.2021.03.033.

12. Roohani S, Ehret F, Kobus M, et al. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: A systematic review. *Radiat Oncol.* 2022;17:159. doi:10.1186/s13014-022-02072-9. 

13. Zerey MM, Gul A, Kalman NS, Hall MD. Hypofractionated radiotherapy for soft tissue sarcomas. *Cancers (Basel).* 2025;17(7):1170. doi:10.3390/cancers17071170. 

14. ESTRO clinical practice guideline on radiotherapy for adult soft tissue sarcoma of the extremities and trunk wall—endorsed by ASTRO. *Radiother Oncol.* 2026;220:111535. doi:10.1016/j.radonc.2026.111535.

 

Translational research

1. Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results. Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC, Kremer S, Tariveranmoshabad M, Ewongwo A, Silvia SKNR, Ogana H, Nemat-Gorgani N, Dubinett SM, Jaycox JR, Felix C, Schaue D, Nelson SD, Levine B, Motamedi K, Ghazikhanian V, Chmielowski B, Reddy V, Singh AS, Trnkova ZJ, Good Z, Quintero M, Crompton JG, Bernthal N, Eilber FC, Moding EJ, Kalbasi A. Cancer Discov. 2026 Jul 1;16(7):1280-1303. doi: 10.1158/2159-8290.CD-25-1132.

2. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy. Rupp L, Resag A, Potkrajcic V, Warm V, Wehner R, Jöhrens K, Bösmüller H, Eckert F, Schmitz M. Front Immunol. 2023 May 16;14:1185197. doi: 10.3389/fimmu.2023.1185197. eCollection 2023.

3. Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications. Forsythe SD, Sivakumar H, Erali RA, Wajih N, Li W, Shen P, Levine EA, Miller KE, Skardal A, Votanopoulos KI. Ann Surg Oncol. 2022 Nov;29(12):7354-7367. doi: 10.1245/s10434-022-12086-y. Epub 2022 Jul 3.

4. Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma. Ashton E, Taly V, Tlemsani C, Boudou-Rouquette P, de Percin S, Noël J, Gaudet-Chardonnet A, Sullo F, Parfait B, Abdelli J, Bruneau T, Larousserie F, Audard V, Larrede S, Blanchet B, Waechter L, Goldwasser F, Laurent-Puig P, Alexandre J, Beinse G. Clin Cancer Res. 2025 Sep 15;31(18):3944-3955. doi: 10.1158/1078-0432.CCR-25-0134.

 

Additional readings

1. Trøstrup H, Bigdeli AK, Krogerus C, Kneser U, Schmidt G, Schmidt VJ. A multidisciplinary approach to complex dermal sarcomas ensures an optimal clinical outcome. Cancers (Basel). 2022;14(7):1693. doi:10.3390/cancers14071693.

2. Stoneham S, Hunter A, Raahimi M, Livesey A, Mitchell CD, Keohane S. Cutaneous sarcoma: a review and practical approach to management. Clin Exp Dermatol. 2023;48(8):866-872. doi:10.1093/ced/llad166.

3. Apalla Z, Liopyris K, Kyrmanidou E, Fotiadou C, Sgouros D, Patsatsi A, Trakatelli MG, Kalloniati E, Lallas A, Lazaridou E. Clinical and dermoscopic characteristics of cutaneous sarcomas: a literature review. Diagnostics (Basel). 2023;13(10):1822. doi:10.3390/diagnostics13101822.

4. Helbig D, Dapper H, Kreuter A, Leiter U, Sirokay J, Ziemer M, Saternus R, Lang BM, Huynh J, Ugurel S, Gschnell M, Utikal J, von Bubnoff D, Persa OD. Adjuvant radiotherapy for pleomorphic dermal sarcoma. EJC Skin Cancer. 2024;2:100255. doi:10.1016/j.ejcskn.2024.100255.

5. Wong GN, Webb A, Gyorki D, McCormack C, Tran P, Ngan SY, Slavin J, Henderson MA. Cutaneous leiomyosarcoma: dermal and subcutaneous. Australas J Dermatol. 2020;61(3):243-249. doi:10.1111/ajd.13307.

6. Fionda B, Loperfido A, Di Stefani A, Lancellotta V, Paradisi A, De Angeli M, Cappilli S, Rossi E, Caretto AA, Zinicola T, Schinzari G, Gentileschi S, Morganti AG, Rembielak A, Peris K, Tagliaferri L. The role of postoperative radiotherapy in the management of dermatofibrosarcoma protuberans: a multidisciplinary systematic review. J Clin Med. 2024;13(6):1798. doi:10.3390/jcm13061798.

7. Yoder AK, Farooqi AS, Wernz C, Subramaniam A, Ravi V, Goepfert R, Sturgis EM, Mitra D, Bishop AJ, Guadagnolo BA. Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: reevaluating the role of surgery and radiation therapy. Head Neck. 2023;45(8):1943-1951. doi:10.1002/hed.27418.

8. Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. Int J Radiat Oncol Biol Phys. 1993;27(5):1057-1061. doi:10.1016/0360-3016(93)90523-X.